Search the Community
Showing results for tags 'tocilizumab'.
Found 2 results
The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis (RA) patients to tocilizumab. RA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. Seminars in Arthritis and Rheumatism, 11/03/2017. (Also see Treatments for Rheumatoid Arthritis and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Short–course tocilizumab (TCZ) increases risk of hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis: a prospective clinical observation. To identify the exact risk of TCZ on HBV infection and the prognosis of TCZ–related HBV reactivation, further studies with larger sample sizes and fewer confounding factors are needed. PubMed, Int J rheumatologist Dis, 02/03/2017. (Also see Rheumatoid Arthritis in Overlap, Clinical Trials and Liver Involvement) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.